Genzyme's CSR Dilemma: How to Play its HAND Custom Case Solution & Analysis

Evidence Brief: Genzyme and the HAND Program

1. Financial Metrics

Cerezyme Pricing: The annual cost per patient for Cerezyme treatment ranges from 150,000 to 300,000 USD, depending on dosage and patient weight.
Company Revenue: Genzyme reported approximately 4.5 billion USD in annual revenue during the period of the case, with Cerezyme accounting for a significant portion of total earnings.
HAND Program Investment: Genzyme allocates a percentage of its annual production of Cerezyme to humanitarian programs. In Egypt, the program supports roughly 100 patients for free.
Market Value: Genzyme maintains high gross margins on its orphan drug portfolio to fund research and development for rare conditions with small patient populations.

2. Operational Facts

Patient Backlog: While 100 Egyptian patients receive free treatment, hundreds more remain on a waiting list without access to the drug.
Product Nature: Cerezyme is a life-sustaining enzyme replacement therapy for Gaucher disease; cessation of treatment leads to rapid health deterioration.
Supply Chain: The drug requires strict cold-chain management and specialized medical administration in clinical settings.
Program Origin: The Humanitarian Assistance for Neglected Diseases (HAND) program was designed as a temporary bridge to demonstrate clinical efficacy and encourage government reimbursement.

3. Stakeholder Positions

Henri Termeer (CEO): Maintains that Genzyme cannot replace the role of the state in providing healthcare but feels a moral obligation to provide initial access.
Egyptian Ministry of Health: Views the high cost of Cerezyme as prohibitive for the national health budget and relies on Genzyme to continue the free program indefinitely.
Patient Advocacy Groups: Demand immediate expansion of the HAND program to include all diagnosed patients, citing the right to life.
Shareholders: Concerned that open-ended philanthropic commitments set a dangerous precedent and threaten the commercial viability of the orphan drug model.

4. Information Gaps

Marginal Cost: The exact marginal cost of producing one unit of Cerezyme is not disclosed in the case text.
Government Budget: Detailed line-item data for the Egyptian Ministry of Health budget for rare diseases is missing.
Alternative Treatments: The case does not provide data on the cost or efficacy of potential competitors or generic entries in the Egyptian market.

Strategic Analysis

1. Core Strategic Question

How can Genzyme transition from an unsustainable philanthropic model to a sustainable commercial or co-pay model in emerging markets without causing a humanitarian crisis or destroying its pricing power in developed nations?

2. Structural Analysis

Applying the Bargaining Power of Buyers and Creating Shared Value frameworks yields the following insights:

Buyer Power: In Egypt, the government acts as a monopsony buyer but refuses to exercise its purchasing power due to high unit costs. This creates a stalemate where the supplier (Genzyme) assumes the full cost of the buyer.
Social Contract: The orphan drug model relies on high prices in wealthy markets to fund R and D. If Genzyme provides the drug for free in one market indefinitely, it weakens the argument for high prices elsewhere.
Value Chain: The bottleneck is not production capacity but the financial infrastructure for reimbursement in developing economies.

3. Strategic Options

Option	Rationale	Trade-offs
Tiered Pricing Model	Establish a price point based on Egypt's GDP or healthcare budget per capita.	Requires the government to commit to a multi-year purchase agreement; risks price leakage to other markets.
Hard Cap on HAND	Freeze the program at 100 patients and refuse new entrants until government funding starts.	Protects financial margins; results in significant negative publicity and patient deaths.
Matching Fund Strategy	Genzyme matches every patient the government pays for with one free patient from HAND.	Creates a direct incentive for government participation; increases total volume of drug provided.

4. Preliminary Recommendation

Genzyme should implement the Matching Fund Strategy combined with Tiered Pricing. This approach forces the Egyptian government to take ownership of its citizens' health while Genzyme maintains its humanitarian commitment. It transforms the relationship from a charity-donor dynamic into a partnership. This path protects the global price floor by labeling the Egyptian price as a specific emerging market exception tied to government volume commitments.

Implementation Roadmap

1. Critical Path

Month 1: Conduct a formal audit of the current Egyptian patient registry to verify clinical need and treatment status.
Month 2: Present the Matching Fund proposal to the Egyptian Ministry of Health, setting a firm deadline for the transition.
Month 3: Establish a third-party trust or foundation to manage the HAND program, removing it from direct corporate marketing control.
Month 4-6: Phase in the first 20 government-funded patients; Genzyme adds 20 from the HAND waiting list.

2. Key Constraints

Political Stability: Shifts in the Egyptian government may reset negotiations, requiring constant high-level diplomatic engagement.
Budgetary Cycles: National health budgets are set annually; Genzyme must align its proposal with the Egyptian fiscal calendar to ensure funds are allocated.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of a total government refusal, Genzyme should not cut off existing patients. Instead, it should apply the cap only to new patients. This avoids the ethical catastrophe of stopping treatment for those already stabilized while creating the necessary pressure on the Ministry of Health to address the growing waiting list. Success will be measured by the ratio of government-funded to HAND-funded patients over a 36-month period.

Executive Review and BLUF

1. BLUF

Genzyme must immediately pivot from pure philanthropy to a co-investment model in Egypt. The current HAND program creates a moral hazard where the Egyptian government avoids its fiscal responsibility because Genzyme fills the gap. By implementing a 1:1 matching program, Genzyme incentivizes state participation while protecting its global pricing integrity. Total withdrawal is ethically and reputationally impossible; indefinite expansion is financially irresponsible. The matching model is the only path that aligns social mission with fiscal reality.

2. Dangerous Assumption

The analysis assumes the Egyptian government prioritizes the lives of Gaucher patients enough to reallocate budget from more common diseases. If the government determines that the cost per quality-adjusted life year for Cerezyme is too high compared to basic interventions, they may never pay, regardless of the incentive.

3. Unaddressed Risks

Reference Pricing Risk: Developed nations may use the lower tiered price in Egypt as a benchmark to demand discounts, threatening 70 percent of Genzyme's global margin.
Logistical Failure: Increased volume through government channels may lead to improper storage or black-market resale, damaging the brand and patient safety.

4. Unconsidered Alternative

The team did not evaluate the possibility of a local production joint venture. While biologics are complex, licensing the fill-finish stage of production to an Egyptian firm could reduce costs, create local jobs, and make it politically easier for the government to justify the expenditure as an investment in national infrastructure.